Effect of oral curcuden on multiple sclerosis patients
Phase 2
- Conditions
- Multiple sclerosis.Demyelinating diseases of the central nervous system(Multiple sclerosis)
- Registration Number
- IRCT20170128032241N2
- Lead Sponsor
- Alborz Nanomed Tech Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 68
Inclusion Criteria
RRMS patients who will receive first-line treatment drugs for one year
Have at least one relapse or active lesion
At least one month has passed since the last attack of the disease
At least one month ha passed from the patient's corticosteroids
Average age of 18 to 60 years
0 No curcumin contraindications
Exclusion Criteria
Progressive MS patients
Patients who have contraindicated curcumin or similar substances
The presence of any internal or systemic illness (such as anemia or liver problems)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Active lesions in the brain and spinal cord (plaque). Timepoint: Before the intervention (month 0) and the sixth month after the intervention. Method of measurement: MRI.;Blood inflammatory factors. Timepoint: Before the intervention (month 0) and the sixth month after the intervention. Method of measurement: Blood Test.
- Secondary Outcome Measures
Name Time Method Clinical relapse within 6 months. Timepoint: Every 6 months. Method of measurement: MRI.;Effect of medication on other MRI parameters such as T2 lesions, new T2 lesions and brain atrophy. Timepoint: Every 6 months. Method of measurement: MRI.;Effect of medication on changes in inflammatory and anti-inflammatory mediators. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Blood test.;Effect of medication on improving patient lifestyle. Timepoint: Before intervention and 6 months after intervention. Method of measurement: EDSS Criteria, Fatigue, Focus, Balance .